Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Alimera Sciences excels in Q1 2024, eyes revenue growth and market expansion

Alimera Sciences' Q1 2024 performance reflects robust revenue growth, profitability improvements, and strategic initiatives to drive product awareness and clinical advancements.
While facing challenges in margin stabilization and cost management, the company is well-positioned to capitalize on opportunities like indication expansion and sales optimization.
Overall, Alimera Sciences' strong financial performance, focus on innovation, and market expansion efforts position it for continued growth and success in the ophthalmic pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 – 15, 2021.

Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.

Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium

Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates

Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, which missed the estimate of $1.06.

Recap: Alimera Sciences Q2 Earnings

ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences Announces Second Quarter 2021 Financial Results

Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time

Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?

ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.

Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021

ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri.

Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist

Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call Transcript

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates

ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the first quarter of 2021. Alimera will host a conference call on April 29, 2021, at 9:00 a.m. ET to discuss these results.

Alimera Sciences Announces First Quarter 2021 Financial Results

On Wednesday, April 28, Alimera Sciences (NASDAQ:ALIM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Outlook For Alimera Sciences

Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence   Amid required stay-at-home orders, many have paused or canceled doctor's appointments over the past 12 months. Recent studies show some of the troubling effects of patients missing out on treatments for vision loss.

Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years

Gracell Biotechnologies

Eli Lilly

Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's.

Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines

ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announced today that Ocumension Therapeutics (Ocumension), a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license agreement for Alimera's 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark ILUVIEN®. The license grants Ocumension the rights to develop and commercialize the product for the treatment of diabetic macular edema and other retina diseases (excluding uveitis) in the Greater China territory and other Western Pacific countries under Ocumension's own distinct trademark. Additionally, Ocumension has made a $10 million equity investment in Alimera via a private offering.

Alimera Sciences Receives $20 Million From Ocumension Therapeutics

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET followed by a live Q&A session with registered investors and other conference attendees. In addition, Mr. Eiswirth will be available for virtual one-on-one meetings the same day.

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.

Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript

Alimera Sciences Reports Fourth Quarter and 2020 Results

ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.

Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time

Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update

ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021.

Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference

Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. President and CEO of the Company, Rick Eiswirth, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "We are an ophthalmology company, so we're focused on finding ways to treat diseases...

News for Alimera Sciences Stock (ALIM)